Patents by Inventor Johannes Lengler

Johannes Lengler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENE THERAPY OF HEMOPHILIA B USING VIRAL VECTORS ENCODING RECOMBINANT FIX VARIANTS WITH INCREASED EXPRESSION
    Publication number: 20240100128
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia B. In some embodiments, the present disclosure provides methods for dosing a hemophilia B patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor IX polypeptide.
    Type: Application
    Filed: February 1, 2023
    Publication date: March 28, 2024
    Inventors: Hanspeter Rottensteiner, Franziska Horling, Johannes Lengler, Friedrich Scheiflinger
  • Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression
    Patent number: 11596671
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia B. In some embodiments, the present disclosure provides methods for dosing a hemophilia B patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor IX polypeptide.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: March 7, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Hanspeter Rottensteiner, Franziska Horling, Johannes Lengler, Friedrich Scheiflinger
  • ADENO-ASSOCIATED VIRUS VECTORS BASED GENE THERAPY FOR HEREDITARY ANGIOEDEMA
    Publication number: 20230043051
    Abstract: The present disclosure provides, among other things, a recombinant adeno-associated virus (rAAV) vector comprising an AAV8 capsid and a codon-optimized SERPING1 sequence encoding a human C1-esterase inhibitor. The disclosure also provides a method of treating a subject having Hereditary angioedema (HAE), comprising administering to the subject in need thereof a recombinant adeno-associated virus (rAAV) vector comprising an AAV8 capsid, and codon-optimized SERPING1 sequences encoding a human C1-esterase inhibitor.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 9, 2023
    Inventors: Matthias Klugmann, Franziska Horling, Johannes Lengler, Patrice Douillard, Friedrich Scheiflinger, Hanspeter Rottensteiner, Bagirath Gangadharan
  • Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
    Patent number: 11492388
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: November 8, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A
    Publication number: 20220213172
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Application
    Filed: January 6, 2022
    Publication date: July 7, 2022
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
    Patent number: 11254731
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: February 22, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • VIRAL VECTORS ENCODING RECOMBINANT FIX WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA B
    Publication number: 20210128700
    Abstract: Codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells are provided, including sequences with high nucleotide sequence identity to the CS02, CS03, CSO4, CS05, and CS06 sequences. Mammalian gene therapy vectors, such as adeno-associated viral vectors, and methods for treating hemophilia B using those vectors are also provided.
    Type: Application
    Filed: October 20, 2020
    Publication date: May 6, 2021
    Inventors: Franziska Horling, Johannes Lengler, Falko-Gunter Falkner, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B
    Patent number: 10842853
    Abstract: Codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells are provided, including sequences with high nucleotide sequence identity to the CS02, CS03, CS04, CS05, and CS06 sequences. Mammalian gene therapy vectors, such as adeno-associated viral vectors, and methods for treating hemophilia B using those vectors are also provided.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: November 24, 2020
    Assignees: Baxalta Incorporated
    Inventors: Franziska Horling, Johannes Lengler, Falko-Gunter Falkner, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • GENE THERAPY OF HEMOPHILIA B USING VIRAL VECTORS ENCODING RECOMBINANT FIX VARIANTS WITH INCREASED EXPRESSION
    Publication number: 20200246437
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia B. In some embodiments, the present disclosure provides methods for dosing a hemophilia B patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor IX polypeptide.
    Type: Application
    Filed: January 30, 2020
    Publication date: August 6, 2020
    Inventors: Hanspeter Rottensteiner, Franziska Horling, Johannes Lengler, Friedrich Scheiflinger
  • VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A
    Publication number: 20190202893
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Application
    Filed: December 5, 2018
    Publication date: July 4, 2019
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A
    Publication number: 20190194295
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Application
    Filed: December 5, 2018
    Publication date: June 27, 2019
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
    Patent number: 10189889
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: January 29, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
    Patent number: 10189888
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: January 29, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • VIRAL VECTORS ENCODING RECOMBINANT FIX WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA B
    Publication number: 20180339026
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia B.
    Type: Application
    Filed: May 22, 2018
    Publication date: November 29, 2018
    Inventors: Franziska Horling, Johannes Lengler, Falko-Gunter Falkner, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A
    Publication number: 20170233455
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Application
    Filed: November 11, 2016
    Publication date: August 17, 2017
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A
    Publication number: 20170226188
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Application
    Filed: November 11, 2016
    Publication date: August 10, 2017
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger